您现在的位置: 首页> 研究主题> 磷脂酶A

磷脂酶A

磷脂酶A的相关文献在1990年到2022年内共计788篇,主要集中在内科学、基础医学、外科学 等领域,其中期刊论文95篇、专利文献73120篇;相关期刊67种,包括中国病理生理杂志、国际检验医学杂志、中华肾脏病杂志等; 磷脂酶A的相关文献由1749位作者贡献,包括于殿宇、刘逸寒、路福平等。

磷脂酶A—发文量

期刊论文>

论文:95 占比:0.13%

专利文献>

论文:73120 占比:99.87%

总计:73215篇

磷脂酶A—发文趋势图

磷脂酶A

-研究学者

  • 于殿宇
  • 刘逸寒
  • 路福平
  • 江连洲
  • 王立琦
  • 许骏
  • 徐正军
  • 周美凤
  • 毛裕民
  • 谢毅
  • 期刊论文
  • 专利文献

搜索

排序:

年份

    • 李振洲; 邵玉凤; 陈胜华; 关晓韵; 吴欣殷; 罗舒榆
    • 摘要: 目的:探讨颈动脉粥样硬化斑块稳定性与血浆脂蛋白相关磷脂酶A2 (Lp-PLA2)水平的相关性.方法:选择185例颈动脉粥样硬化患者作为研究对象,分为稳定斑块组(97例)和不稳定斑块组(88例),应用二维超声对所有斑块特征进行评估,所有对象均进行血浆Lp-PLA2检测.结果:不稳定斑块组血浆Lp-PLA2水平较高,与稳定斑块组间差异有统计学意义(P<0.05).不稳定斑块的形态不规则、表面溃疡、偏心指数>2、斑块内部液化等特征均与血浆高Lp-PLA2有相关性(P<0.05).血浆Lp-PLA2过高是影响颈动脉粥样硬化斑块稳定性的独立危险因素(P<0.05).结论:血浆Lp-PLA2水平与颈动脉粥样硬化斑块稳定性相关,Lp-PLA2过高是影响斑块稳定性的独立危险因素.
    • 李灏; 蔡勇; 黄金波; 袁莉; 杨职
    • 摘要: 目的 探讨载脂蛋白(Apo)及血浆脂蛋白相关磷脂酶A2(Lp-PLA2)与缺血性脑卒中TOAST病因分型的关系.方法 将388例缺血性脑卒中患者按照经典的TOAST病因分型进行分组,分别为心源性脑栓塞(CE)、大动脉粥样硬化性卒中(LAA)、小动脉卒中/腔隙性脑梗死(SAO)、其他原因引发的缺血性卒中(SOE)、原因不明的缺血性卒中(SUE),所有患者次日晨抽取静脉血检测ApoA1、ApoB、ApoH及血浆Lp-PLA2.比较各组年龄、高血压、糖尿病、吸烟、饮酒、血脂异常的暴露率;分析LAA及SAO发病的危险性因素.结果 5组高血压、糖尿病和血脂异常暴露率比较差异有统计学意义(P<0.01);LAA组及SAO组的Lp-PLA2、ApoB水平均高于CE、SOE及SUE组(P<0.05);LAA组及SAO组的ApoA1水平低于CE、SOE及SUE组(P<0.05);Lp-PLA2、ApoB水平是LAA及SAO患者的危险因素,ApoA1是保护性因素.结论 Lp-PLA2及ApoB水平升高是LAA及SAO患者的危险因素,而ApoA1水平升高是保护性因素,血浆Lp-PLA2、ApoB及ApoA1水平检测有助于明确缺血性脑卒中的TOAST病因分型.
    • 陈儒; 田嘉伟; 张文辉; 李荣; 辛辉
    • 摘要: 目的研究Omega-3多不饱和脂肪酸(n-3PUFAS)对稳定型心绞痛病人低密度脂蛋白(LDL)、脂蛋白相关磷脂酶A2(LPPLA2)及脂蛋白a水平的影响,为n-3PUFAS治疗稳定型心绞痛提供临床依据。方法在我院心内科经冠状动脉造影诊断为稳定型心绞痛的病人80例,随机分为对照组和试验组,每组各40例。两组病人均给予常规抗冠心病治疗,如给予阿司匹林、瑞舒伐他汀,抗高血压治疗如给予美托洛尔。试验组病人在常规抗冠心病治疗的基础上每天给予n-3PUFAS胶囊(汤臣倍健牌鱼油软胶囊)1g治疗,对照组病人在规律抗冠心病治疗的基础上给予相同剂量的安慰剂(大豆油胶囊)治疗,疗程均为3个月。治疗前后采集病人的空腹静脉血,检测LPPLA2、LDL及脂蛋白a的水平。结果治疗后两组病人血清LPPLA2水平均较治疗前明显下降,差异有显著意义(t=3.825、2.115,P0.05)。结论 n-3PUFAS可降低稳定型心绞痛病人血液LPPLA2及LDL水平,但对脂蛋白a无明显影响。
    • 付瑞敏; 邢文会; 张红; 张丽琴; 陈五岭
    • 摘要: 为选育有效抑制扩展青霉(Penicillium expansum)的拮抗菌,并初步探讨其抑菌机制.从苹果表面分离到拮抗扩展青霉的菌株BA-16,经形态学、生理生化及16S rRNA基因序列分析,对该菌进行鉴定,并采用低能N+注入技术对其进行诱变选育.采用双酶反应体系检测野生株和突变株对扩展青霉分泌磷脂酶的抑制效果以检测突变效果并探究其抑菌机制.经鉴定,BA-16-8该菌被鉴定为解淀粉芽孢杆菌(Bacillus amyloliquefaciens).低能N+注入技术诱变选育出的突变株BA-16-8抑菌性能显著提高且遗传性能稳定.磷脂酶活性结果显示,相对于野生株,突变株代谢产物可显著抑制病原菌所分泌的磷脂酶A的活性,且其抑制效果随浓度的增高而增强,故推测拮抗菌可能通过该机制起到抑制扩展青霉的作用.本研究对于苹果采后青霉病的生物防治具有良好应用开发前景.
    • 韩伟霞; 高丽芳; 王莹; 张晓琴; 魏荣; 王晨
    • 摘要: Objective To investigate the expressions of IgG subtypes and M-type phospholipase A2 receptor (PLA2R) in membranous nephropathy (MN), and to retrospectively analyze its significance and value of differential di-agnosis in idiopathic membranous nephropathy (IMN) and undetermined atypical membranous nephropathy (UAMN). Methods A total of 120 cases of membranous nephropathy diagnosed by renal biopsy pathology (immunofluores-cence, light microscopy, and electron microscopy) in our hospital between February and September, 2015 were includ-ed in the study. The expressions of IgG subtypes and PLA2R were determined by immunohistochemistry, and retro-spectively analyzed, combined with the clinical data and pathological features. Their value in the differential diagnosis of IMN and UAMN was evaluated. Results ①A total of 120 cases were included, that IMN accounted for 69.2%and UAMN accounted for 30.8%. The average age of onset in the UAMN group was lower than that in the IMN group, and the difference was statistical significance, whereas no statistical difference was found in the level of urinary protein be-tween the two groups. ②The positive rates of IgA, IgM, C3, FRA, and C1q in the UAMN group were higher than those in the IMN group, and there were statistical differences in the expressions of IgA and complement C1q between the two groups. ③Positive IgG4 was mainly expressed in IMN group that the positive rate of IgG4 was significantly higher than the other IgG subtypes, and there was statistical difference between the IMN group and the UAMN group. In the UAMN group, positive IgG1 and IgG2 were highly expressed. The positive rate of IgG4 in the UAMN group was significantly lower than that in the IMN group. ④The positive rate of PLA2R was significantly higher than all IgG subtypes in the IMN group, and there was statistical difference between the IMN group and the UAMN group. ⑤In the evaluation of the value of IMN and UAMN by the differential diagnosis of IgG4 and PLA2R expression, the inten-sity baseline, sensitivity and specifity of IgG4 were 1, 79. 5%, and 59.5%, respectively. The intensity baseline, sensi-tivity and specifity of PLA2R were >1, 90.4%, and 35.1%, respectively. After the evaluation of IgG4 and PLA2R, the sensitivity and specifity were 71.1%and 64.9%, respectively. Conclusion①Determined by immunohistochemistry assay, IgG4 is mainly expressed in IMN group, whereas IgG subtypes, IgG1, IgG2 and IgG4 are highly expressed in UAMN group. ②PLA2R and IgG4 in IMN group show a high positive concordance rate. The application of IgG4 and PLA2R contribute to the differential diagnosis of IMN and UAMN.%目的:通过观察IgG亚型及M型磷脂酶A2受体(PLA2R)在膜性肾病中的表达,回顾性分析二者在特发性膜性肾病(IMN)与病因不明的不典型膜性肾病(UAMN)中的表达意义及鉴别诊断价值。方法收集我中心于2015年2月至9月经肾穿刺活检病理(免疫荧光、光镜、电镜)确诊为膜性肾病120例,对其进行免疫组织化学IgG亚型及PLA2R表达的观察分析,结合其临床资料及病理学特点,进行回顾性统计分析,评价它们在IMN和UAMN鉴别诊断中的价值。结果①共收集病例120例,其中IMN 占69.2%,UAMN占30.8%;UAMN组的平均发病年龄低于IMN组,差异具有统计学意义,组间蛋白尿水平差异无统计学意义。②UAMN组IgA、IgM、C3、FRA、C1q的阳性率均高于IMN组,且IgA及补体C1q的表达中组间差异有统计学意义。③IMN组以IgG4阳性为主,阳性率显著高于其他亚型,且与UAMN组差异有统计学意义;UAMN组IgG1、IgG2均具有较高比例的阳性沉积,IgG4的阳性率明显低于IMN组。④IMN组PLA2R的阳性率显著高于IgG各亚型,且与UAMN组差异有统计学意义。⑤IgG4与PLA2R联合表达鉴别诊断IMN与UAMN的价值评估中,IgG4以强度1为界值,灵敏度为79.5%,特异度为59.5%;PLA2R以强度>1为界值,灵敏度为90.4%,特异度为35.1%;二者联合评价后,灵敏度为71.1%,特异度为64.9%。结论①经免疫组织化学方法测定,IMN组以IgG4沉积为主,而UAMN组存在IgG1、IgG2、IgG4多种亚型的沉积;②PLA2R和IgG4在IMN组具有较高的阳性一致率;IgG4与PLA2R联合应用,有助于IMN与UAMN的鉴别诊断。
    • 曹艳林; 周韦霖; 刘德贝; 雷鸣; 邹飞扬
    • 摘要: [Objective] To explore the relationship of serum lipoprotein associated phospholipase A 2(Lp-PLA2 ) and homocysteine(HCY) with carotid artery atherosclerosis .[Methods]The patients with carotid ath-erosclerotic cerebral infarction(cerebral infarction group ,n =76) and healthy controls(control group ,n =60) were enrolled in the study .Carotid color doppler ultrasonography was used to measure intimal-medial thick-ness(IMT) of internal carotid artery .Serum levels of Lp-PLA2 and HCY in all subjects were examined for cor-relation analysis .[Results] The levels of Lp-PLA2 ,HCY and IMT in cerebral infarction group were signifi-cantly higher than those in control group ( P < 0 .01) .The ratio of vulnerable plaque in cerebral infarction group(39 .2% ) was obviously higher than that in control group(14 .3% ) ,and there was significant difference between two groups( P<0 .05) .Serum levels of Lp-PLA2 and IMT in vulnerable plaque group were obviously higher than those in stable plaque group ,and there we significant difference between two groups ( P<0 .01) . Serum levels of Lp-PLA2 ,HCY and IMT in stable plaque group were higher than those in no plaque group , and there was significant difference( P<0 .05) .The specificity of serum Lp-PLA2 for discriminating vulnera-ble plaque of carotid atherosclerosis was stronger than that of HCY .[Conclusion]Compared with HCY ,serum Lp-PLA2 has better correlation with vulnerable plaque of carotid atherosclerosis .Serum Lp-PLA2 can reflect the unstability of plaque and be used as a serological biomarker to predict cerebral infarction .%[目的]探讨脑梗死患者血清脂蛋白相关磷脂酶A2(Lp-PLA2)及同型半胱氨酸(HCY)水平与颈动脉粥样硬化的相关性。[方法]选择颈动脉粥样硬化性脑梗死患者(脑梗死组,76例)和健康体检者(对照组,60例)为研究对象,应用颈动脉彩色多普勒超声检查颈动脉内膜中层厚度(IM T ),检测所有研究对象血清Lp-PLA2、HCY水平,并行相关分析。[结果]①脑梗死组的Lp-PLA2、HCY、IM T均显著高于对照组,且两组相比较差异均有显著性( P <0.01)。②脑梗死组易损斑块的比例(39.2%)明显高于对照组(14.3%),且两组相比较差异有显著性( P<0.05)。③易损斑块组血清Lp-PLA2、IM T明显高于稳定斑块组,且两者相比较差异有显著性( P <0.01)。④稳定斑块组血清Lp-PLA2、HCY和IM T均高于无斑块组,且两组相比较差异有显著性( P <0.05)。⑤血清Lp-PLA2辅助识别易损斑块特异性高于 HCY。[结论]与 HCY比较,血清Lp-PLA2与颈动脉粥样硬化易损斑块的相关性更好;血清Lp-PLA2能反映斑块的不稳定,可作为临床预测脑梗死的血清学指标。
    • 王敬军; 李君莲; 綦迎成; 刘巨永
    • 摘要: 目的探讨胞浆型磷脂酶(cPL)A2δ的表达与银屑病皮损的关系。方法用逆转录聚合酶链式反应(RT-PCR)检测银屑病组皮损组织和对照组皮肤标本中cPLA2各亚型mRNA表达水平变化,免疫组化法检测2组皮肤标本中cPLA2δ的表达水平。结果银屑病皮损组织cPLA2δmRNA表达显著升高,而其他5个cPLA2亚型表达在银屑病皮损组织几乎没有变化。对照组皮肤组织中cPLA2的6个亚型表达均较低。银屑病组和对照组cPLA2δmRNA表达差异有统计学意义(t=28.563,P <0.01)。银屑病组的cPLA2δ阳性表达率为100%,高于对照组的7.1%(χ2=50.49,P<0.01)。银屑病皮损患者cPLA2δ表达与PASI评分呈正相关(rs=0.89,P<0.01)。结论 cPLA2δ的表达与银屑病皮损炎性发病有关,cPLA2δ可作为银屑病皮损严重程度检测的新靶标。
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号